Autonomous and Rechargeable Microneurostimulator Endoscopically Implantable into the Submucosa
September 27th, 2018
8.2K views
The application of high-frequency low-energetic stimulation can alleviate the symptoms of gastric dysmotility. In this research, a miniature, endoscopically implantable and wirelessly rechargeable device which is implanted into a submucosal pocket is presented. Successful both-way communication and stimulation control were achieved during an experiment on live pig.
Overview
This study investigates a novel approach to alleviate gastric dysmotility using high-frequency low-energetic stimulation via a miniaturized, endoscopically implantable device. The device is designed for submucosal implantation in live pig models, demonstrating successful communication and stimulation control.
Key Study Components
Area of Science
- Neuroscience
- Gastroenterology
- Biomedical Engineering
Background
- Gastric dysmotility is a significant ailment, impacting gastric function and patient quality of life.
- Current methods are often invasive, leading to complications and prolonged recovery.
- New techniques using implantable devices promise to reduce invasiveness.
- This research aims to provide a method that could be applicable in future clinical settings.
Purpose of Study
- To design and test an advanced implantable device for gastric stimulation.
- To explore the method's feasibility and efficacy in live animal models.
- To enhance understanding of gastric motility regulation via electrical stimulation.
Methods Used
- The study utilized a live pig model for the implantation procedure.
- A miniature device designed for submucosal implantation was developed.
- Key steps included PCB assembly, soldering components, and endoscopic implantation techniques.
- Important procedural steps were outlined, focusing on device positioning and securing within the gastric tissue.
Main Results
- Successful implantation and retrieval of data from the device were achieved during experiments.
- The communication process between the device and the external control system was validated.
- Initial outcomes suggest potential for reduced invasiveness in treatment protocols for gastric dysmotility.
- The research lays the groundwork for future exploration of implantable devices in gastrointestinal disorders.
Conclusions
- This study demonstrates an innovative approach to treat gastric dysmotility through minimally invasive techniques.
- Future research could lead to clinical applications for managing gastric disorders.
- The implications extend to enhancing our understanding of gastrointestinal motility and potential therapeutic strategies.
Frequently Asked Questions
What are the advantages of this implantable device?
The device enables a less invasive treatment for gastric dysmotility, reducing recovery time and complications compared to traditional methods.
How is the device implanted?
The device is implanted using an endoscope, which allows precise positioning in the submucosal layer of the stomach with minimal invasion.
What types of data can be obtained from the device?
The device is designed to communicate data regarding electrical stimulation and gastric activity, facilitating analysis of functional outcomes.
Can this method be adapted for other gastrointestinal diseases?
Yes, the novel approach could serve as a foundation for exploring similar techniques in treating various gastrointestinal disorders.
What are some key limitations of the study?
The study is preliminary and based on animal models; further research is needed to assess long-term efficacy and safety in humans.
What safety precautions are necessary during implantation?
Precautions such as wearing gloves and safety glasses are essential while working with electronic components and during the implantation process.
Executive Industry Relevance
Miniaturized, endoscopically implantable neurostimulators represent a significant advance for translational research in gastrointestinal motility disorders. This approach enables less invasive, rechargeable, and wirelessly controlled interventions, supporting mechanistic de-risking and functional target validation in preclinical models. The technology positions R&D teams to explore neuromodulation strategies with improved predictive confidence and workflow integration.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables functional interrogation of neuromodulation hypotheses in disease-relevant in vivo models.
- Supports biological de-risking by allowing controlled, repeatable stimulation and monitoring of gastric tissue responses.
- Facilitates target validation for bioelectronic therapies addressing gastric dysmotility.
Screening & Assay Development
- Provides a platform for standardized, quantitative assessment of stimulation parameters and tissue responses.
- Enables reproducible device placement and stimulation protocols for comparative studies.
- Supports assay development for evaluating neuromodulatory compound or device effects in vivo.
Translational & Preclinical Research
- Aligns with translational biomarker strategies by enabling real-time monitoring and bidirectional communication in large animal models.
- Bridges discovery and preclinical validation by demonstrating device feasibility and functional readouts in physiologically relevant systems.
- Reduces translational risk by providing scalable, minimally invasive implantation workflows.
Pipeline & Workflow Integration
This implantable device methodology fits within the continuum from early discovery through preclinical validation, supporting both hypothesis testing and translational continuity.
- Discovery Biology: Facilitates mechanistic studies of neuromodulation in gastrointestinal tissue.
- Screening: Enables standardized, quantitative readouts for device and stimulation parameter optimization.
- Analytics: Provides bidirectional communication for real-time data acquisition and device control.
- Translational Research: Demonstrates feasibility in large animal models, supporting preclinical advancement.
- Enterprise Reuse: Offers a reusable platform for iterative device and protocol development across programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in neuromodulation research.
- Operational Value: Standardizes device assembly, implantation, and testing for reproducibility and scalability.
- Strategic Value: Improves go/no-go decision-making by enabling robust preclinical evaluation of bioelectronic interventions.
- Portfolio Impact: Supports risk-adjusted prioritization of neuromodulation assets targeting gastrointestinal disorders.
Implementation Considerations
- Requires multidisciplinary expertise in electronics, software, and endoscopic surgical techniques.
- Demands access to specialized instrumentation for device assembly, wireless charging, and bidirectional communication.
- Necessitates rigorous cross-team standardization of implantation and testing protocols.
- Adaptation to other model systems may require device and workflow customization.
- Practical limitations include the need for careful device verification and safety precautions during assembly and implantation.
Biopharma FAQs
Why does null hypothesis testing matter for submucosal neurostimulator validation?
Null hypothesis testing enables objective assessment of whether high-frequency stimulation produces statistically significant modulation of gastric motility in vivo, supporting rigorous target validation and reducing mechanistic uncertainty in early-stage research.
How does independent variable isolation fit the endoscopic implantation workflow?
Isolating stimulation parameters as independent variables during device-controlled experiments allows teams to attribute observed gastric responses specifically to neurostimulation, strengthening mechanistic insights and discovery-stage decision-making.
What do quantitative dependent variable measurements enable in device testing?
Quantitative readouts from bidirectional device communication provide reproducible data on tissue response, enabling comparative analysis of stimulation protocols and supporting robust assay development for neuromodulation research.
Why are replication requirements critical for cross-functional device studies?
Replication ensures that device assembly, implantation, and stimulation protocols yield consistent results across teams, facilitating cross-functional collaboration and reliable data for portfolio advancement decisions.
What statistical analysis capabilities are required before device implementation?
Teams must establish statistical frameworks to analyze stimulation outcomes, assess device performance, and validate reproducibility, ensuring that preclinical findings are robust enough to inform translational and portfolio strategies.
